Smith, Melody http://orcid.org/0000-0002-2702-0381
Dai, Anqi
Ghilardi, Guido
Amelsberg, Kimberly V.
Devlin, Sean M.
Pajarillo, Raymone
Slingerland, John B.
Beghi, Silvia
Herrera, Pamela S.
Giardina, Paul
Clurman, Annelie
Dwomoh, Emmanuel
Armijo, Gabriel
Gomes, Antonio L. C. http://orcid.org/0000-0003-3790-3724
Littmann, Eric R.
Schluter, Jonas http://orcid.org/0000-0002-6214-9367
Fontana, Emily
Taur, Ying http://orcid.org/0000-0002-6601-8284
Park, Jae H. http://orcid.org/0000-0002-2903-5130
Palomba, Maria Lia http://orcid.org/0000-0001-5099-9156
Halton, Elizabeth
Ruiz, Josel
Jain, Tania http://orcid.org/0000-0001-6854-773X
Pennisi, Martina
Afuye, Aishat Olaide http://orcid.org/0000-0002-5751-3283
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Freyer, Craig W. http://orcid.org/0000-0002-6526-8134
Garfall, Alfred
Gier, Shannon
Nasta, Sunita
Landsburg, Daniel
Gerson, James
Svoboda, Jakub
Cross, Justin
Chong, Elise A. http://orcid.org/0000-0001-8895-1625
Giralt, Sergio
Gill, Saar I.
Riviere, Isabelle
Porter, David L.
Schuster, Stephen J.
Sadelain, Michel http://orcid.org/0000-0002-9031-8025
Frey, Noelle
Brentjens, Renier J. http://orcid.org/0000-0002-3364-5388
June, Carl H. http://orcid.org/0000-0003-0241-3557
Pamer, Eric G.
Peled, Jonathan U. http://orcid.org/0000-0002-4029-7625
Facciabene, Andrea http://orcid.org/0000-0002-9563-297X
van den Brink, Marcel R. M. http://orcid.org/0000-0003-0696-4401
Ruella, Marco http://orcid.org/0000-0003-4301-5811
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL125571, R01-HL123340)
American Society of Hematology (AMFDP)
Article History
Received: 8 April 2021
Accepted: 13 January 2022
First Online: 14 March 2022
Change Date: 17 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-02069-7
Competing interests
: M.Sm. has served as a consultant for Janssen and has a patent application related to the microbiome (PCT/US2019/056137). A.L.C.G. is currently employed by Xbiome. E.G.P. serves on the advisory board of Diversigen and has received speaker honoraria from Bristol Myers Squibb, Celgene, Seres Therapeutics, MedImmune, Novartis and Ferring Pharmaceuticals and is an inventor on patent application nos. WPO2015179437A1 and WO2017091753A1; he holds patents that receive royalties from Seres Therapeutics. M.A.P. reports honoraria from AbbVie, Astellas Pharma, Bristol Myers Squibb, Celgene, Equilium, Incyte, Karyopharm, Kite Pharma/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, Takeda and VectivBio. M.A.P. serves on the data and safety monitoring boards of Cidara Therapeutics, Medigene, Sellas Life Sciences and Servier, and the scientific advisory board of NexImmune. M.A.P. has ownership interests in NexImmune and Omeros. M.A.P. has received research support for clinical trials from Incyte, Kite Pharma/Gilead, Miltenyi Biotec and Novartis. J.H.P. has received consulting fees from Amgen, Novartis, Autolus, Kite Pharma, Bristol Myers Squibb, Takeda, Servier, Innate Pharma, Kura Oncology, AstraZeneca, Curocell and Intellia Therapeutics and serves on the scientific advisory board of Artiva. E.A.C. serves on the advisory boards for Novartis, Bristol Myers Squibb and Kite Pharma. J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics and consulting fees from DaVolterra and from MaaT Pharma. J.U.P. has filed intellectual property applications related to the microbiome (reference nos. 62/843,849, 62/977,908 and 15/756,845). M.R.M.B. has received research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer, has consulted, received honoraria from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Merck, Magenta Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven, Priothera, Ceramedix, LyGenesis, Pluto Therapeutics, Novartis (spouse), Kite Pharma (spouse), BeiGene (spouse); he has intellectual property licensing with Seres Therapeutics and Juno Therapeutics and holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). J.Sv. has served as a consultant for Adaptive, AstraZeneca, Atara, Bristol Myers Squibb, Seattle Genetics, Imbrium and Genmab. J.Sv. has received research funding from AstraZeneca, Bristol Myers Squibb, Incyte, Merck, Seattle Genetics, TG Therapeutics and Pharmacyclics. J.Sc. is cofounder of Postbiotics Plus. J.G. reports research funding from Loxo and serves on the advisory boards of Kite Pharma, Genentech, AbbVie and TG Therapeutics. M.Sa. and R.B. hold patents related to CD19 CAR T cells. M.R., S.I.G. and S.J.S. hold patents related to CD19 CAR T cells. M.R. has served as a consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Bayer and AbClon. M.R. receives research funding from AbClon, NanoString and Beckman Coulter. M.R. is the scientific founder of ViTToria Biotherapeutics. C.H.J. has received grant support from Novartis and has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania. He is also a scientific cofounder and holds equity in DeCART Therapeutics and Tmunity Therapeutics. He serves on the board of AC Immune and is a scientific advisor to Cabaletta Bio, Celldex Therapeutics, Carisma Therapeutics, Viracta Therapeutics and WIRB-Copernicus Group. A.G. has research funding from Novartis, Janssen, Tmunity Therapeutics and CRISPR Therapeutics and honoraria from Janssen and GlaxoSmithKline. The other authors declare no competing interests.